BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 1997;25:151-157. [PMID: 9016527 DOI: 10.1093/nar/25.1.151] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Smardová J, Smarda J, Koptíková J. Functional analysis of p53 tumor suppressor in yeast. Differentiation 2005;73:261-77. [PMID: 16138827 DOI: 10.1111/j.1432-0436.2005.00028.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
2 Mccabe M, Dlamini Z. The molecular mechanisms of oesophageal cancer. International Immunopharmacology 2005;5:1113-30. [DOI: 10.1016/j.intimp.2004.11.017] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
3 Chang DL, Qiu W, Ying H, Zhang Y, Chen CY, Xiao ZX. ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2. Oncogene 2007;26:4627-34. [PMID: 17297463 DOI: 10.1038/sj.onc.1210254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
4 Sørlie T, Martel-Planche G, Hainaut P, Lewalter J, Holm R, Børresen-Dale AL, Montesano R. Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines. Br J Cancer 1998;77:1573-9. [PMID: 9635831 DOI: 10.1038/bjc.1998.259] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
5 Nunn J, Scholes A, Liloglou T, Nagini S, Jones A, Vaughan E, Gosney J, Rogers S, Fear S, Field J. Fractional allele loss indicates distinct genetic populations in the development of squamous cell carcinoma of the head and neck (SCCHN). Carcinogenesis 1999;20:2219-28. [DOI: 10.1093/carcin/20.12.2219] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
6 Wang Z, Atencio J, Robinson ES, McCarrey JR. Ultraviolet B-induced melanoma in Monodelphis domestica occurs in the absence of alterations in the structure or expression of the p53 gene. Melanoma Res 2001;11:239-45. [PMID: 11468512 DOI: 10.1097/00008390-200106000-00005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
7 Ito E, Yip KW, Katz D, Fonseca SB, Hedley DW, Chow S, Xu GW, Wood TE, Bastianutto C, Schimmer AD, Kelley SO, Liu F. Potential Use of Cetrimonium Bromide as an Apoptosis-Promoting Anticancer Agent for Head and Neck Cancer. Mol Pharmacol 2009;76:969-83. [DOI: 10.1124/mol.109.055277] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 6.1] [Reference Citation Analysis]
8 Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002;277:18817-26. [PMID: 11893750 DOI: 10.1074/jbc.M201405200] [Cited by in Crossref: 159] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
9 Benninghoff J, Kartarius S, Teleb Z, Selter H, Unteregger G, Zwergel T, Wullich B, Montenarh M. Two different forms of p53 localized differently within cells of urogenital tumours. Cancer Lett 1999;144:55-64. [PMID: 10503878 DOI: 10.1016/s0304-3835(99)00187-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Rabbani F, Cordon-Cardo C. Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol Clin North Am. 2000;27:83-102, ix. [PMID: 10696248 DOI: 10.1016/s0094-0143(05)70237-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Murphy KL, Dennis AP, Rosen JM. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 2000;14:2291-302. [PMID: 11053251 DOI: 10.1096/fj.00-0128com] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 2.9] [Reference Citation Analysis]
12 Hagen J, Tompkins V, Dudakovic A, Weydert JA, Quelle DE. Generation and characterization of monoclonal antibodies to NIAM: a nuclear interactor of ARF and Mdm2. Hybridoma (Larchmt) 2008;27:159-66. [PMID: 18582208 DOI: 10.1089/hyb.2007.0533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lohkamp LN, Schinz M, Gehlhaar C, Guse K, Thomale UW, Vajkoczy P, Heppner FL, Koch A. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. PLoS One 2016;11:e0156422. [PMID: 27253461 DOI: 10.1371/journal.pone.0156422] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
14 Vikhanskaya F, D'Incalci M, Broggini M. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Res. 2000;28:513-519. [PMID: 10606650 DOI: 10.1093/nar/28.2.513] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
15 Inatani H, Yamamoto N, Hayashi K, Kimura H, Takeuchi A, Miwa S, Higuchi T, Abe K, Taniguchi Y, Yamada S, Asai K, Otsuka T, Tsuchiya H. Do Mesenchymal Stem Cells Derived From Atypical Lipomatous Tumors Have Greater Differentiation Potency Than Cells From Normal Adipose Tissues? Clin Orthop Relat Res 2017;475:1693-701. [PMID: 28155209 DOI: 10.1007/s11999-017-5259-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Garcia CA, Ahmadian A, Gharizadeh B, Lundeberg J, Ronaghi M, Nyrén P. Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene. 2000;253:249-257. [PMID: 10940563 DOI: 10.1016/S0378-1119(00)00257-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
17 Chen H, Wang LD, Guo M, Gao SG, Guo HQ, Fan ZM, Li JL. Alterations of p53 and PCNA in cancer and adjacent tissues from concurrent carcinomas of the esophagus and gastric cardia in the same patient in Linzhou, a high incidence area for esophageal cancer in northern China. World J Gastroenterol 2003; 9(1): 16-21 [PMID: 12508343 DOI: 10.3748/wjg.v9.i1.16] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
18 Wei Y, Lin Y, Zhang A, Guo L, Cao J. Evaluation of the noncovalent binding interactions between polycyclic aromatic hydrocarbon metabolites and human p53 cDNA. Science of The Total Environment 2010;408:6285-90. [DOI: 10.1016/j.scitotenv.2010.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
19 Tang KS, Guralnick BJ, Wang WK, Fersht AR, Itzhaki LS. Stability and folding of the tumour suppressor protein p16. J Mol Biol 1999;285:1869-86. [PMID: 9917418 DOI: 10.1006/jmbi.1998.2420] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 4.5] [Reference Citation Analysis]
20 Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst. 1997;89:1844-1851. [PMID: 9414172 DOI: 10.1093/jnci/89.24.1844] [Cited by in Crossref: 168] [Cited by in F6Publishing: 154] [Article Influence: 7.0] [Reference Citation Analysis]
21 Lang C, Unteregger G, Kartarius S, Günther J, Bonkhoff H, Montenarh M, Zwergel T. p53 autoantibodies in patients with urological tumours. Br J Urol 1998;82:721-6. [PMID: 9839589 DOI: 10.1046/j.1464-410x.1998.00814.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Österholm A, Hou S. Splicing mutations at theHPRT locus in human T-lymphocytes in vivo. Environ Mol Mutagen 1998;32:25-32. [DOI: 10.1002/(sici)1098-2280(1998)32:1<25::aid-em3>3.0.co;2-a] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
23 Xu N, Shiraki T, Yamada T, Nakajima M, Gauthier JM, Pfeiffer CJ, Sato S. Nucleotide sequence of the p53 cDNA of beluga whale (Delphinapterus leucas). Gene 2002;288:159-66. [DOI: 10.1016/s0378-1119(02)00472-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Dance-Barnes ST, Kock ND, Floyd HS, Moore JE, Mosley LJ, D'Agostino RB Jr, Pettenati MJ, Miller MS. Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors. Toxicol Appl Pharmacol 2008;231:77-84. [PMID: 18565564 DOI: 10.1016/j.taap.2008.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
25 Groskreutz DJ, Monick MM, Yarovinsky TO, Powers LS, Quelle DE, Varga SM, Look DC, Hunninghake GW. Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells. J Immunol 2007;179:2741-7. [PMID: 17709487 DOI: 10.4049/jimmunol.179.5.2741] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
26 Maggi LB Jr, Winkeler CL, Miceli AP, Apicelli AJ, Brady SN, Kuchenreuther MJ, Weber JD. ARF tumor suppression in the nucleolus. Biochim Biophys Acta 2014;1842:831-9. [PMID: 24525025 DOI: 10.1016/j.bbadis.2014.01.016] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
27 Oku S, Higashi M, Imazono Y, Sueyoshi K, Enokida H, Kubo H, Yonezawa S, Shirahama T. Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract. BJU International 2003;91:109-14. [DOI: 10.1046/j.1464-410x.2003.03057.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Jennings GS, Strauss M. Immortalization of Hepatocytes through Targeted Deregulation of the Cell Cycle. In: Al-rubeai M, editor. Cell Engineering. Dordrecht: Springer Netherlands; 1999. pp. 255-87. [DOI: 10.1007/978-0-585-37971-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Fulci G, Ishii N, Van Meir EG. p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol 1998;8:599-613. [PMID: 9804370 DOI: 10.1111/j.1750-3639.1998.tb00187.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
30 Natsume T, Kobayashi M, Fujimoto S. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer 2001;92:386-94. [DOI: 10.1002/1097-0142(20010715)92:2<386::aid-cncr1334>3.0.co;2-v] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
31 Peng J, Zhan Y, Feng J, Fan S, Zang H. Expression of WDR79 is associated with TP53 mutation and poor prognosis in surgically resected non-small cell lung cancer. J Cancer 2019;10:3046-53. [PMID: 31281482 DOI: 10.7150/jca.30587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chen F, Hou M, Wang J, Chen T, Chen DC, Huang S, Chung Y, Lin S. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan. Cancer Letters 2004;207:59-67. [DOI: 10.1016/j.canlet.2003.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
33 Wang X, Liotta L. Clinical bioinformatics: a new emerging science. J Clin Bioinforma 2011;1:1. [PMID: 21884620 DOI: 10.1186/2043-9113-1-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
34 Agrawal A, Yang J, Murphy RF, Agrawal DK. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. Exp Mol Pathol. 2006;81:115-122. [PMID: 16919268 DOI: 10.1016/j.yexmp.2006.07.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 3.4] [Reference Citation Analysis]
35 Murphy KL, Rosen JM. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene 2000;19:1045-51. [DOI: 10.1038/sj.onc.1203274] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
36 di Tommaso A, Hagen J, Tompkins V, Muniz V, Dudakovic A, Kitzis A, Ladeveze V, Quelle DE. Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Exp Cell Res 2009;315:1326-35. [PMID: 19331830 DOI: 10.1016/j.yexcr.2009.01.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
37 Kadioglu O, Saeed M, Mahmoud N, Azawi S, Mrasek K, Liehr T, Efferth T. Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion. Arch Toxicol 2021;95:959-74. [PMID: 33515271 DOI: 10.1007/s00204-021-02979-4] [Reference Citation Analysis]
38 Sengstag C, Mörbe JL, Weibel B. Codon 249 of the human TP53 tumor suppressor gene is no hot spot for aflatoxin B1 in a heterologous background. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999;430:131-44. [DOI: 10.1016/s0027-5107(99)00186-4] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
39 Ferguson LR. Inhibitors of topoisomerase II enzymes: a unique group of environmental mutagens and carcinogens. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1998;400:271-8. [DOI: 10.1016/s0027-5107(98)00039-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
40 Mccarthy N, Mercer J, Bennett M. APOPTOTIC PROTEINS. Cardiology Clinics 2001;19:75-89. [DOI: 10.1016/s0733-8651(05)70196-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res. 1999;23:871-880. [PMID: 10573131 DOI: 10.1016/s0145-2126(99)00102-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
42 van Slooten HJ, van De Vijver MJ, Borresen AL, Eyfjörd JE, Valgardsdóttir R, Scherneck S, Nesland JM, Devilee P, Cornelisse CJ, van Dierendonck JH. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma. J Pathol 1999;189:504-13. [PMID: 10629550 DOI: 10.1002/(SICI)1096-9896(199912)189:4<504::AID-PATH483>3.0.CO;2-A] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
43 Malik A, Singh H, Andrabi M, Husain SA, Ahmad S. Databases and QSAR for Cancer Research. Cancer Inform 2006;2:117693510600200. [DOI: 10.1177/117693510600200002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
44 Mnjoyan ZH, Dutta R, Zhang D, Teng B, Fujise K. Paradoxical Upregulation of Tumor Suppressor Protein p53 in Serum-Stimulated Vascular Smooth Muscle Cells: A Novel Negative-Feedback Regulatory Mechanism. Circulation 2003;108:464-71. [DOI: 10.1161/01.cir.0000080339.49212.49] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
45 Hesketh R. P53. The Oncogene & Tumour Suppressor Gene Factsbook. Elsevier; 1997. pp. 446-63. [DOI: 10.1016/b978-012344548-3/50085-6] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
46 Blackburn TJ, Ahmed S, Coxon CR, Liu J, Lu X, Golding BT, Griffin RJ, Hutton C, Newell DR, Ojo S, Watson AF, Zaytzev A, Zhao Y, Lunec J, Hardcastle IR. Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and intermediates. Details for the biological evaluation. Further details for the modeling. Table of combustion analysis data. See DOI: 10.1039/c3md00161jClick here for additional data file. Medchemcomm 2013;4:1297-304. [PMID: 24078862 DOI: 10.1039/c3md00161j] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
47 Tompkins VS, Hagen J, Frazier AA, Lushnikova T, Fitzgerald MP, di Tommaso A, Ladeveze V, Domann FE, Eischen CM, Quelle DE. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. J Biol Chem 2007;282:1322-33. [PMID: 17110379 DOI: 10.1074/jbc.M609612200] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
48 Strauss BS. Hypermutability in Carcinogenesis. Genetics 1998;148:1619-26. [DOI: 10.1093/genetics/148.4.1619] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
49 Nikliński J, Niklińska W, Laudanski J, Chyczewska E, Chyczewski L. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer 2001;34:S53-8. [DOI: 10.1016/s0169-5002(01)00345-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
50 Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol 2011;2011:583929. [PMID: 21331359 DOI: 10.1155/2011/583929] [Cited by in Crossref: 129] [Cited by in F6Publishing: 132] [Article Influence: 11.7] [Reference Citation Analysis]
51 Buyru N, Altinisik J, Demokan S, Dalay N. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detection and Prevention 2007;31:207-13. [DOI: 10.1016/j.cdp.2007.04.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
52 López M, Anzola M, Cuevas-salazar N, Aguirre J, Martinez de Pancorbo M. p53, un gen supresor tumoral. Gaceta Médica de Bilbao 2001;98:21-7. [DOI: 10.1016/s0304-4858(01)74350-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
53 Hussain SP, Harris CC. Molecular Epidemiology of Human Cancer. In: Schwab M, Rabes HM, Munk K, Hofschneider HP, editors. Genes and Environment in Cancer. Berlin: Springer Berlin Heidelberg; 1998. pp. 22-36. [DOI: 10.1007/978-3-642-46870-4_2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
54 Heuer DM, Yuan C, Saha S, Archer LA. Effect of topological asymmetry on the electrophoretic mobility of branched DNA structures with and without single-base mismatches. Electrophoresis 2005;26:64-70. [DOI: 10.1002/elps.200406128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
55 Philipson L. Cell Cycle Exit: Growth Arrest, Apoptosis, and Tumor Suppression Revisited. Mol Med 1998;4:205-13. [DOI: 10.1007/bf03401918] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
56 Wang W, Zhu X, Hong X, Zheng L, Zhu H, Hu Y. Identification of novel inhibitors of p53–MDM2 interaction facilitated by pharmacophore-based virtual screening combining molecular docking strategy. Med Chem Commun 2013;4:411. [DOI: 10.1039/c2md20208e] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
57 Will K, Warnecke G, Wiesmüller L, Deppert W. Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing. Proc Natl Acad Sci U S A 1998;95:13681-6. [PMID: 9811860 DOI: 10.1073/pnas.95.23.13681] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 1.6] [Reference Citation Analysis]
58 Moll UM, Schramm LM. p53--an acrobat in tumorigenesis. Crit Rev Oral Biol Med 1998;9:23-37. [PMID: 9488246 DOI: 10.1177/10454411980090010101] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
59 Shakked Z, Yavnilovitch M, Kalb AJ, Kessler N, Wolkowicz R, Rotter V, Haran TE. DNA binding and 3′–5′ exonuclease activity in the murine alternatively-spliced p53 protein. Oncogene 2002;21:5117-26. [DOI: 10.1038/sj.onc.1205667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
60 Lee T, Pelletier J. Dependence of p53-deficient cells on the DHX9 DExH-box helicase. Oncotarget 2017;8:30908-21. [PMID: 28427210 DOI: 10.18632/oncotarget.15889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
61 Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem. 2005;280:39373-39379. [PMID: 16176931 DOI: 10.1074/jbc.M500022200] [Cited by in Crossref: 89] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
62 Mitsumoto Y, Nakajima T, Marutani M, Kashiwazaki H, Moriguchi M, Kimura H, Okanoue T, Kagawa K, Tada M. Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry. Human Pathology 2004;35:350-6. [DOI: 10.1016/j.humpath.2003.09.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
63 Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999;187:8-18. [PMID: 10341702 DOI: 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y] [Cited by in Crossref: 115] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
64 Wang W, Hu Y. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy: p53-MDM2 PATHWAY FOR CANCER THERAPY. Med Res Rev 2012;32:1159-96. [DOI: 10.1002/med.20236] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
65 Garranzo-Asensio M, Guzmán-Aránguez A, Povés C, Fernández-Aceñero MJ, Montero-Calle A, Ceron MÁ, Fernandez-Diez S, Rodríguez N, Gómez de Cedrón M, Ramírez de Molina A, Domínguez G, Barderas R. The specific seroreactivity to ∆Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein. Sci Rep 2019;9:13547. [PMID: 31537884 DOI: 10.1038/s41598-019-49960-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
66 Sankaranarayanan K, Chakraborty R. Ionizing radiation and genetic risks. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2000;453:129-81. [DOI: 10.1016/s0027-5107(00)00107-x] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
67 Yeh YT, Yeh H, Su SH, Lin JS, Lee KJ, Shyu HW, Chen ZF, Huang SY, Su SJ. Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequent apoptosis in oral cancer cells with varying p53 mutations. Free Radic Biol Med 2014;74:1-13. [PMID: 24952138 DOI: 10.1016/j.freeradbiomed.2014.06.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
68 Hollstein M, Moeckel G, Hergenhahn M, Spiegelhalder B, Keil M, Werle-Schneider G, Bartsch H, Brickmann J. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat Res 1998;405:145-54. [PMID: 9748548 DOI: 10.1016/s0027-5107(98)00131-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
69 Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G. Pooled analysis of p53 mutations in hematological malignancies. Hum Mutat 1998;12:4-18. [DOI: 10.1002/(sici)1098-1004(1998)12:1<4::aid-humu2>3.0.co;2-g] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Mitchell PJ, Perez-Nadales E, Malcolm DS, Lloyd AC. Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype. Mol Cell Biol 2003;23:2530-42. [PMID: 12640134 DOI: 10.1128/MCB.23.7.2530-2542.2003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
71 Yang J, Zhang Y. New insight into the role of MDMX in MDM2-mediated p53 degradation and anti-cancer drug development. Oncoscience 2021;8:94-6. [PMID: 34386548 DOI: 10.18632/oncoscience.542] [Reference Citation Analysis]
72 Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010;17:901-911. [PMID: 20379196 DOI: 10.1038/cdd.2010.35] [Cited by in Crossref: 153] [Cited by in F6Publishing: 150] [Article Influence: 12.8] [Reference Citation Analysis]
73 Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 2000;19:889-98. [PMID: 10702797 DOI: 10.1038/sj.onc.1203386] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 2.7] [Reference Citation Analysis]
74 Mary MN, Venot C, Caron de Fromentel C, Debussche L, Conseiller E, Cochet O, Gruel N, Teillaud JL, Schweighoffer F, Tocque B, Bracco L. A tumor specific single chain antibody dependent gene expression system. Oncogene 1999;18:559-64. [PMID: 9927213 DOI: 10.1038/sj.onc.1202377] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
75 Jimenez GS, Bryntesson F, Torres-arzayus MI, Priestley A, Beeche M, Saito S, Sakaguchi K, Appella E, Jeggo PA, Taccioli GE, Wahl GM, Hubank M. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature 1999;400:81-3. [DOI: 10.1038/21913] [Cited by in Crossref: 99] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
76 Ferraiuolo M, Verduci L, Blandino G, Strano S. Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. Int J Mol Sci 2017;18:E961. [PMID: 28467351 DOI: 10.3390/ijms18050961] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
77 Demirhan O, Taştemir D, Hastürk S, Kuleci S, Hanta İ. Alterations in p16 and p53 genes and chromosomal findings in patients with lung cancer: Fluorescence in situ hybridization and cytogenetic studies. Cancer Epidemiology 2010;34:472-7. [DOI: 10.1016/j.canep.2010.03.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
78 Martínez JLS, Morales CMC, Ortega SS, López-nevot MÁ. Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. Clin Transl Oncol 2005;7:156-64. [DOI: 10.1007/bf02708753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
79 Sedlacek Z, Kodet R, Poustka A, Goetz P. A database of germline p53 mutations in cancer-prone families. Nucleic Acids Res 1998;26:214-5. [PMID: 9399838 DOI: 10.1093/nar/26.1.214] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
80 Rasool S, Ganai BA, Sameer AS, Masood A. Esophageal Cancer: Associated Factors with Special Reference to the Kashmir Valley. Tumori 2012;98:191-203. [DOI: 10.1177/030089161209800203] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 5.3] [Reference Citation Analysis]
81 Williams TM, Lee H, Cheung MW, Cohen AW, Razani B, Iyengar P, Scherer PE, Pestell RG, Lisanti MP. Combined Loss of INK4a and Caveolin-1 Synergistically Enhances Cell Proliferation and Oncogene-induced Tumorigenesis. Journal of Biological Chemistry 2004;279:24745-56. [DOI: 10.1074/jbc.m402064200] [Cited by in Crossref: 57] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
82 Tollini LA, Zhang Y. p53 Regulation Goes Live-Mdm2 and MdmX Co-Star: Lessons Learned from Mouse Modeling. Genes Cancer 2012;3:219-25. [PMID: 23150755 DOI: 10.1177/1947601912454732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
83 Perlow RA, Broyde S. Evading the proofreading machinery of a replicative DNA polymerase: induction of a mutation by an environmental carcinogen. J Mol Biol 2001;309:519-36. [PMID: 11371169 DOI: 10.1006/jmbi.2001.4674] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
84 . Review. Biological Chemistry 1998;379:377-400. [DOI: 10.1515/bchm.1998.379.4-5.377] [Cited by in Crossref: 36] [Cited by in F6Publishing: 54] [Article Influence: 1.5] [Reference Citation Analysis]
85 Wierstra I. The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res 2013;118:97-398. [PMID: 23768511 DOI: 10.1016/B978-0-12-407173-5.00004-2] [Cited by in Crossref: 93] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
86 Nguyen H, Asseline U, Dupret D, Nguyen T.thuong. Studies towards the design of a modified GC base pair with stability similar to that of the AT base pair. Tetrahedron Letters 1997;38:4083-6. [DOI: 10.1016/s0040-4039(97)00829-0] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
87 Montesano R, Hall J. Environmental causes of human cancers. Eur J Cancer 2001;37 Suppl 8:S67-87. [PMID: 11602374 DOI: 10.1016/s0959-8049(01)00266-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
88 Pfeifer GP, Denissenko MF. Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations? Environ Mol Mutagen 1998;31:197-205. [PMID: 9585258 DOI: 10.1002/(sici)1098-2280(1998)31:3<197::aid-em1>3.0.co;2-i] [Cited by in Crossref: 41] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
89 Li Z, Yu A, Weiner AM. Adenovirus Type 12-Induced Fragility of the Human RNU2 Locus Requires p53 Function. J Virol 1998;72:4183-91. [DOI: 10.1128/jvi.72.5.4183-4191.1998] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
90 Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 2006;130:73-9. [PMID: 16401470 DOI: 10.1053/j.gastro.2005.10.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 5.0] [Reference Citation Analysis]
91 Peltonen J, Welsh JA, Vähäkangas KH. Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene? Hum Exp Toxicol 2007;26:9-18. [PMID: 17334176 DOI: 10.1177/0960327107071918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
92 Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1998;1378:F21-59. [DOI: 10.1016/s0304-419x(98)00010-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 1.6] [Reference Citation Analysis]
93 Li G, Ji Y, Liu C, Li J, Zhou Y. Reduced levels of p15INK4b, p16INK4a, p21cip1 and p27kip1 in pancreatic carcinoma. Mol Med Rep 2012;5:1106-10. [PMID: 22293850 DOI: 10.3892/mmr.2012.771] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
94 Lewis SP, Willis AN, Johnson AE, Resau J, Burnatowska-hledin MA. Mutational analysis of VACM-1/cul5 exons in cancer cell lines: MUTATIONAL ANALYSIS OF VACM-1/cul5 EXONS. APMIS 2011;119:421-30. [DOI: 10.1111/j.1600-0463.2011.02747.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
95 Olsen RJ, Tarantolo SR, Hinrichs SH. Molecular approaches to sarcoma therapy. Sarcoma 2002;6:27-42. [PMID: 18521343 DOI: 10.1080/13577140220127530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
96 Fujita Y, Yamamoto N, Kato I, Iwai S, Ono K, Sakurai Y, Ohnishi K, Ohnishi T, Yura Y. Induction of multinucleation in oral squamous cell carcinoma tissue with mutated p53 surviving boron neutron capture therapy. International Journal of Radiation Biology 2010;87:293-301. [DOI: 10.3109/09553002.2011.530336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
97 Fu DJ, Tang K, Braun A, Reuter D, Darnhofer-Demar B, Little DP, O'Donnell MJ, Cantor CR, Köster H. Sequencing exons 5 to 8 of the p53 gene by MALDI-TOF mass spectrometry. Nat Biotechnol 1998;16:381-4. [PMID: 9555731 DOI: 10.1038/nbt0498-381] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 3.7] [Reference Citation Analysis]
98 Ribeiro RC, Pinto EM, Zambetti GP. Familial predisposition to adrenocortical tumors: Clinical and biological features and management strategies. Best Practice & Research Clinical Endocrinology & Metabolism 2010;24:477-90. [DOI: 10.1016/j.beem.2010.03.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
99 Chen Y, Fujita T, Zhang D, Doan H, Pinkaew D, Liu Z, Wu J, Koide Y, Chiu A, Lin CC, Chang JY, Ruan KH, Fujise K. Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. J Biol Chem 2011;286:32575-85. [PMID: 21795694 DOI: 10.1074/jbc.M110.217836] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
100 Mokdad-Gargouri R, Belhadj K, Gargouri A. Translational control of human p53 expression in yeast mediated by 5'-UTR-ORF structural interaction. Nucleic Acids Res 2001;29:1222-7. [PMID: 11222773 DOI: 10.1093/nar/29.5.1222] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
101 Bäckvall H, Wassberg C, Berne B, Ponten F. Similar UV responses are seen in a skin organ culture as in human skin in vivo. Exp Dermatol 2002;11:349-56. [PMID: 12190944 DOI: 10.1034/j.1600-0625.2002.110409.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
102 Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 2003;1002:217-35. [PMID: 14751837 DOI: 10.1196/annals.1281.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
103 Zorić A, Horvat A, Slade N. Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis 2013;34:522-9. [PMID: 23188674 DOI: 10.1093/carcin/bgs370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
104 Kim KH, Cho Y, Lee J, Jeong H, Lee Y, Kim SI, Kim CH, Lee HW, Nam KT. Sexually dimorphic leanness and hypermobility in p16Ink4a/CDKN2A-deficient mice coincides with phenotypic changes in the cerebellum. Sci Rep 2019;9:11167. [PMID: 31371816 DOI: 10.1038/s41598-019-47676-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
105 Zhang C, Berndt-Paetz M, Neuhaus J. Identification of Key Biomarkers in Bladder Cancer: Evidence from a Bioinformatics Analysis. Diagnostics (Basel) 2020;10:E66. [PMID: 31991631 DOI: 10.3390/diagnostics10020066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
106 Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genetics and Cytogenetics 2002;133:1-23. [DOI: 10.1016/s0165-4608(01)00626-4] [Cited by in Crossref: 130] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
107 Ratner D, Peacocke M, Zhang H, Ping XL, Tsou HC. UV-specific p53 and PTCH mutations in sporadic basal cell carcinoma of sun-exposed skin. J Am Acad Dermatol 2001;44:293-7. [PMID: 11174390 DOI: 10.1067/mjd.2001.112361] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
108 Lopez-Crapez E, Bibeau F, Thézenas S, Ychou M, Simony-Lafontaine J, Thirion A, Azria D, Grenier J, Senesse P. p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis. Br J Cancer. 2005;92:2114-2121. [PMID: 15956964 DOI: 10.1038/sj.bjc.6602622] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
109 Cachot J, Cherel Y, Galgani F, Vincent F. Evidence of p53 mutation in an early stage of liver cancer in European flounder, Platichthys flesus (L.). Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2000;464:279-87. [DOI: 10.1016/s1383-5718(99)00205-3] [Cited by in Crossref: 11] [Article Influence: 0.5] [Reference Citation Analysis]
110 Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale AL. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 1998;78:375-81. [PMID: 9703286 DOI: 10.1038/bjc.1998.502] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
111 Shi ST, Yang GY, Wang LD, Xue Z, Feng B, Ding W, Xing EP, Yang CS. Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis. 1999;20:591-597. [PMID: 10223186 DOI: 10.1093/carcin/20.4.591] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 2.3] [Reference Citation Analysis]
112 Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, Mackie DI, Roman DL, Van Rheeden R, Darbro B, Tompkins VS, Quelle DE. RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts. PLoS One 2013;8:e80228. [PMID: 24282525 DOI: 10.1371/journal.pone.0080228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
113 Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 2002;277:43359-68. [PMID: 12213815 DOI: 10.1074/jbc.M205573200] [Cited by in Crossref: 103] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
114 Miller MS. Tumor Suppressor Genes in Rodent Lung Carcinogenesis—Mutation ofp53Does Not Appear to be an Early Lesion in Lung Tumor Pathogenesis. Toxicology and Applied Pharmacology 1999;156:70-7. [DOI: 10.1006/taap.1998.8618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
115 Tang X, Milyavsky M, Goldfinger N, Rotter V. Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene 2007;26:7302-12. [PMID: 17533371 DOI: 10.1038/sj.onc.1210542] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
116 Xiong L, Kou F, Yang Y, Wu J. A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop. J Cell Biol 2007;178:995-1007. [PMID: 17846171 DOI: 10.1083/jcb.200703044] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
117 Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21:5063-5070. [PMID: 11438662 DOI: 10.1128/mcb.21.15.5063-5070.2001] [Cited by in Crossref: 139] [Cited by in F6Publishing: 81] [Article Influence: 6.6] [Reference Citation Analysis]
118 Reis RM, Herva R, Brandner S, Koivukangas J, Mironov N, Bär W, Kleihues P, Ohgaki H. Second Primary Glioblastoma. J Neuropathol Exp Neurol 2001;60:208-15. [DOI: 10.1093/jnen/60.2.208] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
119 Xue Y, Wang S, Feng X. Influence of magnesium ion on the binding of p53 DNA-binding domain to DNA-response elements. J Biochem 2009;146:77-85. [PMID: 19297420 DOI: 10.1093/jb/mvp048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
120 Powell BV, Basu AK. 6-Nitrochrysene-Derived C8-2'-Deoxyadenosine Adduct: Synthesis of Site-Specific Oligodeoxynucleotides and Mutagenicity in Escherichia coli. Chem Res Toxicol 2020;33:604-13. [PMID: 31903755 DOI: 10.1021/acs.chemrestox.9b00429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Taubert H, Berger D, Hinze R, Meye A, Würl P, Hogendoorn PC, Holzhausen HJ, Schmidt H, Rath FW. How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone? Cancer Lett 1998;123:147-51. [PMID: 9489481 DOI: 10.1016/s0304-3835(97)00423-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
122 Lutz WK, Fekete T, Vamvakas S. Position- and base pair-specific comparison of p53 mutation spectra in human tumors: elucidation of relationships between organs for cancer etiology. Environ Health Perspect 1998;106:207-11. [PMID: 9494124 DOI: 10.1289/ehp.98106207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
123 Okamoto T, Suzuki T, Yamamoto N. Microarray fabrication with covalent attachment of DNA using bubble jet technology. Nat Biotechnol 2000;18:438-41. [PMID: 10748527 DOI: 10.1038/74507] [Cited by in Crossref: 306] [Cited by in F6Publishing: 247] [Article Influence: 13.9] [Reference Citation Analysis]
124 Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma 2014;55:1625-34. [PMID: 24144307 DOI: 10.3109/10428194.2013.856007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
125 Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene--two products--two pathways. Trends Biochem Sci 1998;23:291-6. [PMID: 9757829 DOI: 10.1016/s0968-0004(98)01236-5] [Cited by in Crossref: 175] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
126 Wang W, Shangguan S, Qiu N, Hu C, Zhang L, Hu Y. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1. Bioorg Med Chem 2013;21:2879-85. [PMID: 23601819 DOI: 10.1016/j.bmc.2013.03.061] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
127 Xue Y, Wang S, Feng X. Spectrometric Studies on Interaction Between Metal Ions and DNA-Binding Domain of Tumor Suppressor Protein p53. Chinese Journal of Analytical Chemistry 2009;37:1131-6. [DOI: 10.1016/s1872-2040(08)60122-x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
128 Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 1998;12:2997-3007. [PMID: 9765202 DOI: 10.1101/gad.12.19.2997] [Cited by in Crossref: 544] [Cited by in F6Publishing: 539] [Article Influence: 22.7] [Reference Citation Analysis]
129 Sugimoto M, Gromley A, Sherr CJ. Hzf, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage. Mol Cell Biol 2006;26:502-12. [PMID: 16382142 DOI: 10.1128/MCB.26.2.502-512.2006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
130 Parant JM, Reinke V, Mims B, Lozano G. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene 2001;270:277-83. [PMID: 11404026 DOI: 10.1016/s0378-1119(01)00432-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
131 Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A 1998;95:2834-7. [PMID: 9501176 DOI: 10.1073/pnas.95.6.2834] [Cited by in Crossref: 133] [Cited by in F6Publishing: 147] [Article Influence: 5.5] [Reference Citation Analysis]
132 Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol. 2005;205:130-144. [PMID: 15641015 DOI: 10.1002/path.1692] [Cited by in Crossref: 117] [Cited by in F6Publishing: 110] [Article Influence: 6.9] [Reference Citation Analysis]
133 Duan X, Li J. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis. Medicine (Baltimore) 2017;96:e7856. [PMID: 28885338 DOI: 10.1097/MD.0000000000007856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
134 Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B, Bracco L. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 1999;18:551-7. [PMID: 9927212 DOI: 10.1038/sj.onc.1202338] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 2.2] [Reference Citation Analysis]
135 Ahmed FE. Molecular approaches for detection of mutations. Journal of Environmental Science and Health, Part C 1998;16:47-80. [DOI: 10.1080/10590509809373498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
136 Yin D, Xie D, Hofmann WK, Miller CW, Black KL, Koeffler HP. Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 2002;21:8372-8. [PMID: 12447702 DOI: 10.1038/sj.onc.1206031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
137 Zerp SF, van Elsas A, Peltenburg LT, Schrier PI. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br J Cancer 1999;79:921-6. [PMID: 10070891 DOI: 10.1038/sj.bjc.6690147] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 2.4] [Reference Citation Analysis]
138 Verselis SJ, Rheinwald JG, Fraumeni JF Jr, Li FP. Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene 2000;19:4230-5. [PMID: 10980596 DOI: 10.1038/sj.onc.1203758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
139 Floyd HS, Jennings-Gee JE, Kock ND, Miller MS. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. Mol Carcinog 2006;45:506-17. [PMID: 16482519 DOI: 10.1002/mc.20181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
140 Tiwary R, Yu W, Sanders BG, Kline K. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res 2011;13:R1. [PMID: 21214929 DOI: 10.1186/bcr2801] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
141 Tavtigian SV, Chenevix-Trench G. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Biomark Med 2014;8:589-603. [PMID: 24796624 DOI: 10.2217/bmm.13.143] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
142 Ricker CA, Woods AD, Simonson W, Lathara M, Srinivasa G, Rudzinski ER, Mansoor A, Irwin RG, Keller C, Berlow NE. Refractory alveolar rhabdomyosarcoma in an 11-year-old male. Cold Spring Harb Mol Case Stud 2021;7:a005983. [PMID: 33436392 DOI: 10.1101/mcs.a005983] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Yuan C, Rhoades E, Heuer DM, Archer LA. Mismatch-induced DNA unbending upon duplex opening. Biophys J 2005;89:2564-73. [PMID: 16085769 DOI: 10.1529/biophysj.105.065722] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
144 Veldhoen N, Watterson J, Brash M, Milner J. Identification of tumour-associated and germ line p53 mutations in canine mammary cancer. Br J Cancer 1999;81:409-15. [PMID: 10507764 DOI: 10.1038/sj.bjc.6690709] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
145 Emamzadah S, Tropia L, Vincenti I, Falquet B, Halazonetis TD. Reversal of the DNA-binding-induced loop L1 conformational switch in an engineered human p53 protein. J Mol Biol 2014;426:936-44. [PMID: 24374182 DOI: 10.1016/j.jmb.2013.12.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
146 Hupp TR, Lane DP, Ball KL. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J. 2000;352 Pt 1:1-17. [PMID: 11062053 DOI: 10.1042/0264-6021:3520001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
147 Zhou J, Qiao X, Xiao L, Sun W, Wang L, Li H, Wu Y, Ding X, Hu X, Zhou C, Zhang J. Identification and characterization of the novel protein CCDC106 that interacts with p53 and promotes its degradation. FEBS Letters 2010;584:1085-90. [DOI: 10.1016/j.febslet.2010.02.031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
148 Nourbakhsh M, Farzaneh S, Taghikhani A, Zarghi A, Noori S. The Effect of a Newly Synthesized Ferrocene Derivative against MCF-7 Breast Cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/STAT3 Signaling Pathway. ACAMC 2020;20:875-86. [DOI: 10.2174/1871520620666200101151743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
149 Fong V, Osterbur M, Capella C, Kim YE, Hine C, Gorbunova V, Seluanov A, Dewhurst S. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells. PLoS One 2011;6:e28714. [PMID: 22174876 DOI: 10.1371/journal.pone.0028714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
150 Moodley D, Mody GM, Chuturgoon AA. Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis—a pilot study. Clin Rheumatol 2010;29:1099-105. [DOI: 10.1007/s10067-010-1505-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
151 Paunesku T, Zhang Y, Gemmell M, Woloschak GE. p53 Gene deletions in paraffin-preserved lymphoid tumors from irradiated mice. Leukemia Research 2000;24:511-7. [DOI: 10.1016/s0145-2126(00)00005-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
152 Muller M. Cellular Senescence: Molecular Mechanisms, In Vivo Significance, and Redox Considerations. Antioxidants & Redox Signaling 2009;11:59-98. [DOI: 10.1089/ars.2008.2104] [Cited by in Crossref: 167] [Cited by in F6Publishing: 152] [Article Influence: 12.8] [Reference Citation Analysis]
153 Tavassoli M, Brunel N, Maher R, Johnson NW, Soussi T. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. Int J Cancer 1998;78:390-1. [PMID: 9766578 DOI: 10.1002/(SICI)1097-0215(19981029)78:3<390::AID-IJC23>3.0.CO;2-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
154 Muto T, Wakui S, Takahashi H, Maekawa S, Masaoka T, Ushigome S, Furusato M. p53 Gene Mutations Occurring in Spontaneous Benign and Malignant Mammary Tumors of the Dog. Vet Pathol 2000;37:248-53. [DOI: 10.1354/vp.37-3-248] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
155 Hussain S, Harris CC. Molecular epidemiology of human cancer. Toxicology Letters 1998;102-103:219-25. [DOI: 10.1016/s0378-4274(98)00310-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
156 Wang T, Shao X, Cai W, Xue Y, Wang S, Feng X. Predicting the coordination geometry for Mg2+ in the p53 DNA-binding domain: insights from computational studies. Phys Chem Chem Phys 2011;13:1140-51. [PMID: 21076775 DOI: 10.1039/c0cp00678e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
157 Korgaonkar C, Zhao L, Modestou M, Quelle DE. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 2002;22:196-206. [PMID: 11739734 DOI: 10.1128/MCB.22.1.196-206.2002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
158 F. Clausen OP, Lothe RA, Børresen-dale A, Angelis PD, Chen Y, Rognum TO, Meling GI. Association of p53 Accumulation With TP53 Mutations, Loss of Heterozygosity at 17p13, and DNA Ploidy Status in 273 Colorectal Carcinomas: . Diagnostic Molecular Pathology 1998;7:215-23. [DOI: 10.1097/00019606-199808000-00006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
159 Römer L, Klein C, Dehner A, Kessler H, Buchner J. p53 – ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte. Angew Chem 2006;118:6590-611. [DOI: 10.1002/ange.200600611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
160 Fontana R, Ranieri M, La Mantia G, Vivo M. Dual Role of the Alternative Reading Frame ARF Protein in Cancer. Biomolecules 2019;9:E87. [PMID: 30836703 DOI: 10.3390/biom9030087] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
161 Giel-Pietraszuk M, Hoffmann M, Dolecka S, Rychlewski J, Barciszewski J. Palindromes in proteins. J Protein Chem 2003;22:109-13. [PMID: 12760415 DOI: 10.1023/a:1023454111924] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
162 Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001-5014. [PMID: 9724636 DOI: 10.1093/emboj/17.17.5001] [Cited by in Crossref: 726] [Cited by in F6Publishing: 746] [Article Influence: 30.3] [Reference Citation Analysis]
163 Niemantsverdriet M, Jongmans W, Backendorf C. Radiation response and cell cycle regulation of p53 rescued malignant keratinocytes. Experimental Cell Research 2005;310:237-47. [DOI: 10.1016/j.yexcr.2005.07.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
164 Moll UM, Concin N. p53 in Human Cancer — Somatic and Inherited Mutations and Mutation-independent Mechanisms. In: Zambetti GP, editor. The p53 Tumor Suppressor Pathway and Cancer. Boston: Springer US; 2005. pp. 115-54. [DOI: 10.1007/0-387-30127-5_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
165 Ferraiuolo M, Di Agostino S, Blandino G, Strano S. Oncogenic Intra-p53 Family Member Interactions in Human Cancers. Front Oncol. 2016;6:77. [PMID: 27066457 DOI: 10.3389/fonc.2016.00077] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
166 Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, Barale R, Gemignani F, Landi S. DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat 2010;31:456-65. [PMID: 20127977 DOI: 10.1002/humu.21214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
167 Wang Y, Weng H, Zhang Y, Long Y, Li Y, Niu Y, Song F, Bu Y. The PRR11-SKA2 Bidirectional Transcription Unit Is Negatively Regulated by p53 through NF-Y in Lung Cancer Cells. Int J Mol Sci 2017;18:E534. [PMID: 28257042 DOI: 10.3390/ijms18030534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
168 Viotti J, Duplan E, Caillava C, Condat J, Goiran T, Giordano C, Marie Y, Idbaih A, Delattre J, Honnorat J, Checler F, Alves da Costa C. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. Oncogene 2014;33:1764-75. [DOI: 10.1038/onc.2013.124] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
169 Kaneko K, Katagiri A, Konishi K, Kurahashi T, Ito H, Kumekawa Y, Yamamoto T, Muramoto T, Kubota Y, Nozawa H, Makino R, Kushima M, Imawari M. Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus. Br J Cancer 2007;96:492-8. [PMID: 17285122 DOI: 10.1038/sj.bjc.6603582] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
170 Irimia M, Fraga MF, Sanchez-cespedes M, Esteller M. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 2004;23:8695-9. [DOI: 10.1038/sj.onc.1207914] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
171 Schwarz RE, Donohue CA, Sadava D, Kane SE. Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. Cancer Letters 2003;189:59-68. [DOI: 10.1016/s0304-3835(02)00501-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
172 Fujita Y, Kato I, Iwai S, Ono K, Suzuki M, Sakurai Y, Ohnishi K, Ohnishi T, Yura Y. Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma. Radiat Oncol 2009;4:63. [PMID: 20003329 DOI: 10.1186/1748-717X-4-63] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
173 Tollini LA, Jin A, Park J, Zhang Y. Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage. Cancer Cell 2014;26:235-47. [PMID: 25117711 DOI: 10.1016/j.ccr.2014.06.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
174 Römer L, Klein C, Dehner A, Kessler H, Buchner J. p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts. Angew Chem Int Ed 2006;45:6440-60. [DOI: 10.1002/anie.200600611] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 4.6] [Reference Citation Analysis]
175 Keohavong P, Gao WM, Mady HH, Kanbour-Shakir A, Melhem MF. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Cancer Lett 2004;212:121-30. [PMID: 15246568 DOI: 10.1016/j.canlet.2004.03.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
176 Dahabreh IJ, Schmid CH, Lau J, Varvarigou V, Murray S, Trikalinos TA. Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol 2013;177:1317-25. [PMID: 23729685 DOI: 10.1093/aje/kws394] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
177 Mir R, Masroor M, Javid J, Ahamad I, Farooq S, Yadav P, Zuberi M, Lone M, Ray PC, Saxena A. Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients. South Asian J Cancer 2016;5:33-6. [PMID: 27169122 DOI: 10.4103/2278-330X.179701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
178 McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol 1999;188:322-8. [PMID: 10419603 DOI: 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
179 Taja-Chayeb L, Vidal-Millán S, Gutiérrez-Hernández O, Trejo-Becerril C, Pérez-Cárdenas E, Chávez-Blanco A, de la Cruz-Hernández E, Dueñas-González A. Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome. World J Surg Oncol 2009;7:97. [PMID: 20017945 DOI: 10.1186/1477-7819-7-97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
180 Taubert H, Meye A, Bache M, Hinze R, Holzhausen H, Schmidt H, Rath F, Dunst J, Würl P. p53 status in radiation-induced soft-tissue sarcomas. Strahlenther Onkol 1998;174:427-30. [DOI: 10.1007/bf03038565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
181 Monti O, Damalas A, Strano S, Blandino G. P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells. In: Hainaut P, Wiman KG, editors. 25 Years of p53 Research. Dordrecht: Springer Netherlands; 2007. pp. 223-32. [DOI: 10.1007/978-1-4020-2922-6_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
182 Yang L, Sasaki MS. Trans-regulated silencing and reactivation of TP53 tumor suppressor gene in malignant transformation and its reversion. Jpn J Cancer Res 2000;91:1111-8. [PMID: 11092975 DOI: 10.1111/j.1349-7006.2000.tb00893.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
183 Liang Y, Wu J, Stancel GM, Hyder SM. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol. 2005;93:173-182. [PMID: 15860260 DOI: 10.1016/j.jsbmb.2004.12.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
184 Welsh JA, Castrén K, Vähäkangas KH. Single-strand conformation polymorphism analysis to detect p53 mutations: characterization and development of controls. Clinical Chemistry 1997;43:2251-5. [DOI: 10.1093/clinchem/43.12.2251] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
185 Lassus P, Bertrand C, Zugasti O, Chambon J, Soussi T, Mathieu-mahul D, Hibner U. Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant. Oncogene 1999;18:4699-709. [DOI: 10.1038/sj.onc.1202841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
186 Martinez R, Schackert HK, von Kannen S, Lichter P, Joos S, Schackert G. Independent molecular development of metachronous glioblastomas with extended intervening recurrence-free interval. Brain Pathol 2003;13:598-607. [PMID: 14655763 DOI: 10.1111/j.1750-3639.2003.tb00488.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
187 Taubert H, Meye A, Würl P. Soft Tissue Sarcomas and p53 Mutations. Mol Med 1998;4:365-72. [DOI: 10.1007/bf03401743] [Cited by in Crossref: 23] [Article Influence: 1.0] [Reference Citation Analysis]
188 Lubin DJ, Butler JS, Loh SN. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function. J Mol Biol 2010;395:705-16. [PMID: 19913028 DOI: 10.1016/j.jmb.2009.11.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
189 Will K, Warnecke G, Albrechtsen N, Boulikas T, Deppert W. High affinity MAR-DNA binding is a common property of murine and human mutant p53. J Cell Biochem 1998;69:260-70. [DOI: 10.1002/(sici)1097-4644(19980601)69:3<260::aid-jcb4>3.0.co;2-p] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
190 Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-59. [PMID: 9393858 DOI: 10.1016/s0092-8674(00)80452-3] [Cited by in Crossref: 1075] [Cited by in F6Publishing: 524] [Article Influence: 43.0] [Reference Citation Analysis]
191 Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol 2011;225:479-89. [PMID: 21952947 DOI: 10.1002/path.2971] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
192 Basu AK. DNA Damage, Mutagenesis and Cancer. Int J Mol Sci 2018;19:E970. [PMID: 29570697 DOI: 10.3390/ijms19040970] [Cited by in Crossref: 111] [Cited by in F6Publishing: 96] [Article Influence: 27.8] [Reference Citation Analysis]
193 Lunardi A, Di Minin G, Provero P, Dal Ferro M, Carotti M, Del Sal G, Collavin L. A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network. Proc Natl Acad Sci U S A 2010;107:6322-7. [PMID: 20308539 DOI: 10.1073/pnas.1002447107] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]